バイオテク分野における好奇な金融工学の事例
本記事は、バイオテク業界で見られる金融工学の興味深い事例を紹介する。医薬品開発特有の長期間・高リスクな資金調達において、株式や負債の枠を超えた創造的な金融スキームが活用される実態を解説。透明性と倫理の観点から業界が直面する課題にも触れている。
関連記事
Job seekers face a tough environment, but widespread AI-caused job losses have been overblown so far. Instead, AI is creating demand for workers with AI skills, while those who don't adapt may face replacement. Companies are building smaller, AI-native teams as AI makes individuals more productive.
YC's official advice urges founders to be precise and honest about distinguishing between pilots, bookings, revenue, and recurring revenue, warning against confusing one category for another.
The article examines how 4,000 companies faced a disruptive technology in the early 20th century, with only one surviving. It explores why leaders often fail to adapt to technological changes that threaten their existing business models.
While employment changes due to AI are expected to become significant over time, immediate widespread disruption is not anticipated. The transition will likely be gradual rather than sudden.
Andrew Ng writes from the World Economic Forum that businesses need to move beyond incremental AI efficiency gains to achieve transformative impact. He argues that workflow redesign, rather than isolated AI projects, is key to creating significant business value, using loan processing as an example where end-to-end changes can transform product offerings.